MiR-101 promotes breast cancer cell apoptosis by targeting Janus Kinase 2

Cellular Physiology and Biochemistry

Volumn 34, Issue 2, 2014, Pages 413-422

  Wang, Lu ^a   Li, Linqiang ^b   Guo, Rui ^a   Li, Xuelian ^a   Lu, Ying ^a   Guan, Xiaoxiang ^a   Gitau, Samuel Chege ^a   Wang, Leimin ^a   Xu, Chaoqian ^a   Yang, Baofeng ^a   Shan, Hongli ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Jak2; miR 101

Indexed keywords

CASPASE 3; JANUS KINASE 2; MICRORNA 101; AMO 101; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MICRORNA; MIRN101 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MCF 7 CELL LINE; MOLECULAR MECHANICS; MTT ASSAY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BREAST CARCINOMA; CANCER CELL; DOWN REGULATION; GENE SILENCING; LIMIT OF QUANTITATION; PROTEIN DEFECT; BREAST TUMOR; ENZYMOLOGY; FEMALE; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; JANUS KINASE 2; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84904529533     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000363010     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
3. Harry BL, Eckhardt SG, Jimeno A: JAK2 inhibition for the treatment of hematologic and solid malignancies. Expert Opin Investig Drugs 2012;21:637-655.
4. Behera R, Kumar V, Lohite K, Karnik S, Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis 2010;31:192-200.
5. Sakai I, Kraft AS: The kinase domain of Jak2 mediates induction of Bcl-2 and delays cell death in hematopoietic cells. J Biol Chem 1997;272:12350-12358.
6. Verma A, Kambhampati S, Parmar S, Platanias LC: Jak family of kinases in cancer. Cancer and Metastasis Reviews 2003;22:423-434.
7. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
8. Gu S, Jin L, Zhang F, Sarnow P, Kay MA: Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol 2009;16:144-150.
9. Lujambio A, Lowe SW: The microcosmos of cancer. Nature 2012;482:347-355.
10. Han ZB, Yang Z, Chi Y, Zhang L, Wang Y, Ji Y, Wang J, Zhao H, Han ZC: MicroRNA-124 suppresses breast cancer cell growth and motility by targeting CD151. Cell Physiol Biochem 2013;31:823-832.
11. Li LQ, Li XL, Wang L, Du WJ, Guo R, Liang HH, Liu X, Liang DS, Lu YJ, Shan HL, Jiang HC: Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell Physiol Biochem 2012;30:631-641.
12. Zhang L, Yang L, Liu X, Chen W, Chang L, Chen L, Loera S, Chu P, Huang WC, Liu YR, Yen Y: MiR-657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin-like enhancer protein 1 through NF-kappaB pathways. Hepatology 2013;57:1919-1930.
13. Mott JL, Kobayashi S, Bronk SF, Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007;26:6133-6140.
14. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009;106:3207-3212.
15. Strillacci A, Valerii MC, Sansone P, Caggiano C, Sgromo A, Vittori L, Fiorentino M, Poggioli G, Rizzello F, Campieri M, Spisni E: Loss of miR-101 expression promotes Wnt/beta-catenin signalling pathway activation and malignancy in colon cancer cells. J Pathol 2013;229:379-389.
16. Huang Y, Chen HC, Chiang CW, Yeh CT, Chen SJ, Chou CK: Identification of a two-layer regulatory network of proliferation-related microRNAs in hepatoma cells. Nucleic Acids Res 2012;40:10478-10493.
17. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695-1699.
18. Shan H, Zhang Y, Lu Y, Pan Z, Cai B, Wang N, Li X, Feng T, Hong Y, Yang B: Down-regulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res 2009;83:465-472.
19. Lu Y, Zhang Y, Wang N, Pan Z, Gao X, Zhang F, Shan H, Luo X, Bai Y, Sun L, Song W, Xu C, Wang Z, Yang B: MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation 2010;122:2378-2387.
20. Zhao L, Sun Y, Hou Y, Peng Q, Wang L, Luo H, Tang X, Zeng Z, Liu M: MiRNA expression analysis of cancer-associated fibroblasts and normal fibroblasts in breast cancer. Int J Biochem Cell Biol 2012;44:2051-2059.
21. Lee YS, Dutta A: MicroRNAs in cancer. Annu Rev Pathol l2009;4:199-227.
22. Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, Sarkar FH: Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012;72:335-345.
23. Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado B, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, Oliveira C: Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol 2012;228:31-44.
24. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, Zhuang SM: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009;69:1135-1142.
25. He XP, Shao Y, Li XL, Xu W, Chen GS, Sun HH, Xu HC, Xu X, Tang D, Zheng XF, Xue YP, Huang GC, Sun WH: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J 2012;279:4201-4212.
26. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC: Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 2012;72:3091-3104.
27. Sachdeva M, Wu H, Ru P, Hwang L, Trieu V, Mo YY: MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene 2011;30:822-831.
28. Zhu QY, Liu Q, Chen JX, Lan K, Ge BX: MicroRNA-101 targets MAPK phosphatase-1 to regulate the activation of MAPKs in macrophages. J Immunol 2010;185:7435-7442.
29. Verma A, Kambhampati S, Parmar S, Platanias LC: Jak family of kinases in cancer. Cancer Metastasis Rev 2003;22:423-434.
30. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-497.
31. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S: Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-3117.